Elevated serum KIF20A in hepatocellular carcinoma: exploring its potential as a circulating biomarker

Background/Aims: To evaluate serum KIF20A expression in hepatocellular carcinoma (HCC) and assess its association with HCC status using a bioinformatics-guided clinical RT-qPCR approach. Methods: This cross-sectional study included 110 participants: 50 with HCC, 10 with chronic hepatitis C virus (HCV) infection without HCC, and 50 healthy controls. Serum hsa-miR-5192, HSPA1B, LPH02229A/CRHR1-IT1, and KIF20A were quantified by RT-qPCR as relative quantification (RQ). Alpha-fetoprotein (AFP) was the conventional comparator. Secondary analyses evaluated AFP with KIF20A using logistic regression, AUC comparison, and repeated stratified 10-fold cross-validation. Results: KIF20A showed significant overall differential expression (P=0.003), with higher expression in HCC than in healthy controls (P=0.007) and the HCV non-HCC group (P=0.004). Median KIF20A RQ was 2.95 in HCC, 0.40 in healthy controls, and 0.255 in HCV. For HCC versus all non-HCC participants, KIF20A remained associated with HCC after accounting for AFP (OR 2.10 per 1-SD increase in log-transformed KIF20A; 95% CI 1.01-4.37; P=0.048), but the combined model did not materially improve discrimination over AFP alone (AUC 0.968 vs 0.964; DeLong P=0.606). Conclusions: Serum KIF20A showed HCC-associated upregulation and retained an exploratory association with HCC after accounting for AFP. However, it did not provide meaningful incremental discrimination beyond AFP; the small disease-control group and absence of external validation preclude claims of HCC specificity or clinical diagnostic readiness.

Authors

Institutions

Publication Details

Journal
Journal of Liver Cancer
Published
2026-11-19
DOI
https://doi.org/10.17998/jlc.2026.11.06
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Elevated serum KIF20A in hepatocellular carcinoma: exploring its potential as a circulating biomarker

Rania EL-Lethy Abd EL- Hamed, Mohga S. Abdalla, Sara H. A. Agwa, Marwa Matboli et al.
Journal of Liver Cancer
Hepatocellular Carcinoma Treatment and Prognosis
article

Elevated serum KIF20A in hepatocellular carcinoma: exploring its potential as a circulating biomarker

Rania EL-Lethy Abd EL- Hamed, Mohga S. Abdalla, Sara H. A. Agwa, Marwa Matboli, Mahmoud Ashraf Adly Mahgoub
article en

Abstract

Background/Aims: To evaluate serum KIF20A expression in hepatocellular carcinoma (HCC) and assess its association with HCC status using a bioinformatics-guided clinical RT-qPCR approach. Methods: This cross-sectional study included 110 participants: 50 with HCC, 10 with chronic hepatitis C virus (HCV) infection without HCC, and 50 healthy controls. Serum hsa-miR-5192, HSPA1B, LPH02229A/CRHR1-IT1, and KIF20A were quantified by RT-qPCR as relative quantification (RQ). Alpha-fetoprotein (AFP) was the conventional comparator. Secondary analyses evaluated AFP with KIF20A using logistic regression, AUC comparison, and repeated stratified 10-fold cross-validation. Results: KIF20A showed significant overall differential expression (P=0.003), with higher expression in HCC than in healthy controls (P=0.007) and the HCV non-HCC group (P=0.004). Median KIF20A RQ was 2.95 in HCC, 0.40 in healthy controls, and 0.255 in HCV. For HCC versus all non-HCC participants, KIF20A remained associated with HCC after accounting for AFP (OR 2.10 per 1-SD increase in log-transformed KIF20A; 95% CI 1.01-4.37; P=0.048), but the combined model did not materially improve discrimination over AFP alone (AUC 0.968 vs 0.964; DeLong P=0.606). Conclusions: Serum KIF20A showed HCC-associated upregulation and retained an exploratory association with HCC after accounting for AFP. However, it did not provide meaningful incremental discrimination beyond AFP; the small disease-control group and absence of external validation preclude claims of HCC specificity or clinical diagnostic readiness.

Journal of Liver Cancer
Ain Shams University (EG), Helwan University (EG)
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon